Table 4. Multivariable Regression Results Using the Derived Total Score.
| Variable | Mean difference (95% CI)a | P Value | P Value for Interaction |
|---|---|---|---|
| Total synkinesis | |||
| Baseline SAQ | <.001 | ||
| Every 31-point increase for males aged 53, total dose 20 U, 33 mo after injection | 22.73 (15.14 to 30.32) | ||
| Age | .03 | .58 | |
| Every 10-y increase for a baseline score of 50 | 2.21 (0.18 to 4.23) | ||
| Sex | .03 | .42 | |
| Male vs female with the same baseline score of 50 | 8.27 (0.94 to 15.60) | ||
| Time | .55 | .71 | |
| Every 48-mo increase for a baseline score of 50 | −1.69 (−4.72 to 1.35) | ||
| Total dose | .01 | .37 | |
| Every 20-U increase for a baseline score of 50 | 3.54 (0.82 to 6.25) | ||
| Oro-ocular synkinesis (Q1-Q3) | |||
| Baseline SAQ | <.001 | ||
| Every 42-point increase for males aged 53, eye dose 5 U, mouth dose 5 U, 33 mo after injection | 30.58 (23.26 to 37.90) | ||
| Age | .66 | .76 | |
| Every 10-y increase for a baseline score of 58.3 | 1.16 (−1.43 to 3.76) | ||
| Sex | .14 | .09 | |
| Male vs female with the same baseline score of 58.3 | 7.77 (−1.12 to 16.66) | ||
| Time | .41 | .48 | |
| Every 48-mo increase for baseline score of 58.3 | −1.72 (−5.57 to 2.14) | ||
| Periocular dose | .25 | .10 | |
| Every 7.5 U increase for a baseline score of 58.3 | 1.10 (−2.82 to 5.01) | ||
| Perioral dose | .41 | .89 | |
| Every 3.75-U increase for a baseline score of 58.3 | 1.23 (−1.22 to 3.67) | ||
| Oculo-oral synkinesis (Q5-Q7) | |||
| Baseline SAQ | <.001 | ||
| Every 42-point increase for males aged 53 y, eye dose of 5 U, mouth dose of 5 U, 33 mo after injection | 31.29 (24.05 to 38.52) | ||
| Age | .26 | .77 | |
| Every 10-y increase with a baseline score of 58.3 | 1.76 (−1.20 to 4.72) | ||
| Sex | .13 | .10 | |
| Male vs female with the same baseline score of 58.3 | 9.02 (−0.07 to 18.11) | ||
| Time | .90 | .65 | |
| Every 48-mo increase for a baseline score of 58.3 | 0.33 (−3.65 to 4.31) | ||
| Periocular dose | .09 | .47 | |
| Every 7.5-U increase for a baseline score of 58.3 | 2.98 (0.31 to 5.65) | ||
| Perioral Dose | .02 | .01 | |
| Every 3.75-U increase for a baseline score of 58.3 | 1.04 (−0.27 to 2.34) | ||
| Every 3.75-U increase for a baseline score of 20.0 | 3.66 (1.08 to 6.24) |
Abbreviations: Q, question; SAQ, Synkinesis Assessment Questionnaire.
a
Mean difference in postinjection derived score.